ReviewToxins2014
Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions.
Review in Toxins, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 59 citations in OpenAlex.
- Lamotrigine-Induced Toxic Epidermal Necrolysis with Multiorgan Failure, Pneumatosis Intestinalis and Chronic Ocular Complications.Life (Basel, Switzerland) · 2026Article
- Etoricoxib and its hidden risks: a case-based review of dermatological, hematological, and cardiovascular complications.EXCLI journal · 2025Review
- Serum Concentrations of IL-18, IL-21, IL-22, IL-23, IL-27, and IL-31 in Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Their Correlation With Disease Severity.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2025Article
- Coronavirus-disease-2019-associated Stevens-Johnsons syndrome in a 15-year-old boy: a case report and review of the literature.Journal of medical case reports · 2024Review
- Association of Human Leukocyte Antigen Alleles with Carbamazepine- or Lamotrigine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in an Iranian Population: A Case-control Study.Iranian journal of medical sciences · 2023Article
- Allopurinol-Induced Stevens-Johnson Syndrome (SJS).Clinical pharmacology : advances and applications · 2023Article
- Case report: Successful immunomodulators combined with electromagnetic field therapy in a patient with methazolamide-induced Steven Johnson syndrome/toxic epidermal necrolysis overlap.Frontiers in medicine · 2023Article
- The Role ofAllergy, asthma & immunology research · 2021Article
- Corona virus disease 2019-associated Stevens-Johnson syndrome: a case report.BMC ophthalmology · 2021Article
- Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021Review
- Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation.Journal of the American Academy of Dermatology · 2021Article
- A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?Clinical and molecular allergy : CMA · 2020Article
- Attenuation of Wnt/β-catenin signaling in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.International journal of biological sciences · 2020Article
- Stevens-Johnson syndrome/toxic epidermal necrolysis: treatment with low-dose corticosteroids, vitamin C and thiamine.BMJ case reports · 2019Article
- The Fas Signaling Pathway Is a Common Genetic Risk Factor for Severe Cutaneous Drug Adverse Reactions Across Diverse Drugs.Allergy, asthma & immunology research · 2018Article
- Adverse Immunologically Mediated Oral Mucosal Reactions to Systemic Medication: Lichenoid Tissue Reaction/Interface Dermatitis-Stomatitis, Autoimmune Vesiculobullous Disease, and IgE-Dependent and Immune Complex Reactions.Journal of immunology research · 2018Review
- Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions.Seminars in immunopathology · 2018Review
- Diverse expression of TNF-α and CCL27 in serum and blister of Stevens-Johnson syndrome/toxic epidermal necrolysis.Clinical and translational allergy · 2018Article
- Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.Advances in therapy · 2017Review
- Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN), are rare but life-threatening conditions induced mainly by a variety of drugs. Until now, an effective treatment for SJS/TEN still remains unavailable. Current studies have suggested that the pathobiology of drug-mediated SJS and TEN involves major histocompatibility class (MHC) I-restricted activation of cytotoxic T lymphocytes (CTLs) response. This CTLs response requires several cytotoxic signals or mediators, including granulysin, perforin/granzyme B, and Fas/Fas ligand, to trigger extensive keratinocyte death. In this article, we will discuss the cytotoxic mechanisms of severe cutaneous adverse reactions and their potential applications on therapeutics for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.